Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
Oral supplements are available over the counter in various doses and dosage forms
Following multiple doses, mean insulin-like growth factor (IGF-1) levels remained above baseline for up to 28 days
The peptide proceeded through Phase IIb clinical trials for obesity, where it demonstrated favourable safety but failed to meet weight-loss endpoints at the doses tested
Key benefits include: Higher energy levels: This supplement helps decrease fatigue levels, which can enable you to stay more active throughout the day and consistently maintain your exercise routine, supporting your overall fitness and well-being
41,42 Specialist gastroenterologist advice is recommended before pursuing such a strategy
US$ 25.07
US$ 28.76
US$ 22.25
US$ 24.43
US$ 20.44
US$ 27.44
US$ 25.57
US$ 22.69
US$ 20.09
